These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 12070055)
1. Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass? Pauwels R Am J Respir Crit Care Med; 2002 Jun; 165(12):1579-80. PubMed ID: 12070055 [No Abstract] [Full Text] [Related]
2. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Hattotuwa KL; Gizycki MJ; Ansari TW; Jeffery PK; Barnes NC Am J Respir Crit Care Med; 2002 Jun; 165(12):1592-6. PubMed ID: 12070058 [TBL] [Abstract][Full Text] [Related]
3. Contemporary opinions on administration of inhaled glucocorticosteroids in the treatment of chronic obstructive pulmonary disease. Podstawka A; Mosiewicz J; Myśliński W Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):491-7. PubMed ID: 16146136 [TBL] [Abstract][Full Text] [Related]
6. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. John M; Bosse S; Oltmanns U; Schumacher A; Witt C Respir Med; 2005 Nov; 99(11):1418-24. PubMed ID: 15894479 [TBL] [Abstract][Full Text] [Related]
7. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Thompson WH; Carvalho P; Souza JP; Charan NB Lung; 2002; 180(4):191-201. PubMed ID: 12391509 [TBL] [Abstract][Full Text] [Related]
8. [Inhaled glucocorticosteroids in the treatment of asthma and chronic obstructive pulmonary disease]. Obojski A; Dobek R; Panaszek B Pneumonol Alergol Pol; 2004; 72(5-6):226-32. PubMed ID: 15757265 [TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK; Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444 [TBL] [Abstract][Full Text] [Related]
10. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD. Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076 [TBL] [Abstract][Full Text] [Related]
11. [The role of inhalatory glucocorticosteroids in the treatment of chronic obstructive pulmonary disease]. Ovcharenko SI; Golikova EP Ter Arkh; 2005; 77(11):81-7. PubMed ID: 16404869 [No Abstract] [Full Text] [Related]
12. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302 [TBL] [Abstract][Full Text] [Related]
15. Safety of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD). Med Lett Drugs Ther; 2010 May; 52(1339):41-2. PubMed ID: 20508579 [No Abstract] [Full Text] [Related]
16. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552 [TBL] [Abstract][Full Text] [Related]
17. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766 [TBL] [Abstract][Full Text] [Related]
18. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Sin DD; Lacy P; York E; Man SF Am J Respir Crit Care Med; 2004 Oct; 170(7):760-5. PubMed ID: 15229100 [TBL] [Abstract][Full Text] [Related]
19. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. Suissa S Am J Respir Crit Care Med; 2008 Aug; 178(4):322-3. PubMed ID: 18676961 [No Abstract] [Full Text] [Related]
20. [Combination of beta-1 agonist and corticosteroid is advantageous not only in asthma. COPD patients spared exacerbations]. MMW Fortschr Med; 2002 Oct; 144(44):55. PubMed ID: 12494604 [No Abstract] [Full Text] [Related] [Next] [New Search]